Actinium Pharmaceuticals (ATNM) 10-K2023 FY Annual report

Filed: 29 Mar 24, 4:58pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: afflicted, aid, ANDA, annuity, Antonio, arena, Ariceum, art, ARTbio, bifunctional, Biogen, biotech, BlackRock, block, blocking, CDMO, centrally, championed, chimerism, CIRARA, Clarity, CODM, continent, contributor, Curium, deliberately, disqualifying, documentary, EANM, EBMT, EHA, eleven, endeavor, enrichment, episode, eradicate, explanation, extortion, fall, fibroblast, finite, flexibility, fragment, Glasgow, hamper, Henry, heralding, HMA, hope, hot, Hudson, imaging, IRC, Italy, Jr, Keytruda, kinase, lapse, largest, Latin, lifetime, Lutathera, majeure, maker, mCi, meaningfully, membrane, merit, MOA, multiplying, mutant, negligible, neuroendocrine, NK, opposition, parent, payer, pembrolizumab, Persistence, Perspective, pharmacoeconomic, Pharmacy, Pluvicto, possessing, poster, predefined, pretax, proactively, procedural, procedure, procurement, proliferation, provoke, radiochemical, radiology, ramp, rapporteur, reconciling, recycling, referencing, Refractor, regiment, renowned, revolution, scalable, scFv, Scheitleg, SNMMI, SOHO, Southwestern, Spain, spell, spent, subscription, suppressor, TCJA, territorial, tyrosine, unaudited, undergone, undertook, underway, unenforceable, uptake, USPTO, UT, vulnerability, Wagner, wealth, Western, withdrawn

Removed: accounted, advancing, auxiliary, Carey, cohort, continuation, coping, correction, diagnostic, John, learning, move, prolonged, quantify, rational, recession, rental, resurgence, School, spread, Subtopic, topline, unsuccessful, worsening

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

ATNM similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

Independent Registered Public Accounting Firm’s Consent

We consent to the incorporation by reference in the Registration Statement of Actinium Pharmaceuticals, Inc. on Pre-effective amendment No. 1 to Form S-3 (File No. 333-273911) and on Form S-8 (File No. 333-266996, 333-231391, 333-223741, 333-197283) of our report dated March 29, 2024, with respect to our audits of the consolidated financial statements of Actinium Pharmaceuticals, Inc. as of December 31, 2023 and 2022 and for each of the two years in the period ended December 31, 2023, which report is included in this Annual Report on Form 10-K of Actinium Pharmaceuticals, Inc. for the year ended December 31, 2023.

/s/ Marcum llp

Marcum llp

Houston, Texas

March 29, 2024